Bio Medica Laboratories Limited is a pharmaceutical manufacturing company engaged in the production of formulations and healthcare products. The company earns revenue mainly through manufacturing and supplying pharmaceutical products, including injectables, tablets, capsules, dry syrups, ointments, and OTC products for domestic and export markets. Its products are used by hospitals, healthcare institutions, pharmacies, and pharmaceutical companies. The company also focuses on contract manufacturing and formulation development for third-party clients.

The Company is led by Promoter, i.e., MR. MUKESH MEHTA AND MR. PRADEEP MEHTA

The Revenues from operations for the Period ended on Nov 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 2,862.81 Lakh, ₹ 3,832.50 Lakh, ₹ 1,534.42 Lakh, and ₹ 1,624.96 Lakh, The EBITDA for the Period ended on Nov 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 1,344.72 Lakh, ₹ 1,521.33 Lakh, ₹ 563.13 Lakh, and ₹ 169.89 Lakh, The Profit after Tax for the Period ended on Nov 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹ 866.39 Lakh, ₹ 979.49 Lakh, ₹ 249.87 Lakh, and ₹ 33.35 Lakh, respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue  EPS of ₹10.67 and post-issue EPS of ₹7.79 for FY25. The pre-issue P/E ratio is 13.03x,while the post-issue P/E ratio is 17.85x against the Industry P/E ratio is 24x The company's ROE for FY25 is 99.59% and RoNW is 99.59% The Annualised EPS is ₹ 10.33x and P/E is ₹ 13.45x , These metrics suggest that the IPO is Fully priced.

 
The Grey Market Premium (GMP) of Bio Medica Laboratories showing listing gains of 0%.Given the company's financial performance and the valuation of the IPO, we recommend  Investors to Avoid to the Bio Medica Laboratories Limited, IPO for Listing gain or Long Term Purposes.